Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 8 | 2023 | 132 | 2.850 |
Why?
|
| Opioid-Related Disorders | 13 | 2023 | 367 | 2.710 |
Why?
|
| Opiate Substitution Treatment | 8 | 2023 | 80 | 1.510 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2021 | 179 | 1.270 |
Why?
|
| Amphetamine-Related Disorders | 3 | 2021 | 125 | 1.170 |
Why?
|
| Methamphetamine | 3 | 2021 | 233 | 1.080 |
Why?
|
| Cocaine-Related Disorders | 6 | 2017 | 246 | 1.070 |
Why?
|
| Methadone | 6 | 2023 | 169 | 0.940 |
Why?
|
| Tai Ji | 1 | 2023 | 38 | 0.890 |
Why?
|
| Dextroamphetamine | 1 | 2021 | 36 | 0.830 |
Why?
|
| Analgesics, Opioid | 6 | 2023 | 501 | 0.820 |
Why?
|
| Sertraline | 3 | 2017 | 47 | 0.730 |
Why?
|
| Patient Compliance | 3 | 2016 | 249 | 0.700 |
Why?
|
| Central Nervous System Stimulants | 1 | 2021 | 255 | 0.660 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2014 | 21 | 0.600 |
Why?
|
| Amines | 2 | 2014 | 46 | 0.600 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2014 | 76 | 0.580 |
Why?
|
| Depression | 3 | 2014 | 595 | 0.490 |
Why?
|
| Child Abuse | 1 | 2016 | 170 | 0.480 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2010 | 394 | 0.460 |
Why?
|
| Methadyl Acetate | 2 | 2010 | 11 | 0.460 |
Why?
|
| Narcotics | 2 | 2010 | 107 | 0.430 |
Why?
|
| Adult | 19 | 2023 | 14207 | 0.400 |
Why?
|
| Double-Blind Method | 5 | 2021 | 742 | 0.360 |
Why?
|
| Reward | 1 | 2010 | 123 | 0.360 |
Why?
|
| Young Adult | 6 | 2021 | 4318 | 0.320 |
Why?
|
| Behavior Therapy | 1 | 2010 | 203 | 0.320 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2014 | 46 | 0.310 |
Why?
|
| Humans | 24 | 2023 | 54284 | 0.290 |
Why?
|
| Female | 19 | 2021 | 28441 | 0.290 |
Why?
|
| Pilot Projects | 4 | 2021 | 808 | 0.290 |
Why?
|
| Male | 18 | 2021 | 27334 | 0.290 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 70 | 0.290 |
Why?
|
| Anxiety | 2 | 2022 | 279 | 0.270 |
Why?
|
| Narcotic Antagonists | 4 | 2021 | 127 | 0.260 |
Why?
|
| Retrospective Studies | 6 | 2022 | 6432 | 0.250 |
Why?
|
| Health Status | 1 | 2006 | 368 | 0.240 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 692 | 0.240 |
Why?
|
| Veterans | 2 | 2010 | 629 | 0.240 |
Why?
|
| Disulfiram | 2 | 2013 | 11 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2019 | 684 | 0.210 |
Why?
|
| Outpatients | 1 | 2022 | 123 | 0.200 |
Why?
|
| Naloxone | 2 | 2013 | 61 | 0.190 |
Why?
|
| Time Factors | 4 | 2011 | 3213 | 0.190 |
Why?
|
| Quality of Life | 1 | 2006 | 922 | 0.180 |
Why?
|
| Pain | 1 | 2023 | 405 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 248 | 0.180 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 377 | 0.180 |
Why?
|
| Self Report | 3 | 2016 | 204 | 0.180 |
Why?
|
| Middle Aged | 11 | 2021 | 13088 | 0.180 |
Why?
|
| Patient Dropouts | 2 | 2016 | 60 | 0.170 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 30 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2019 | 85 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2023 | 5604 | 0.170 |
Why?
|
| Ambulatory Care | 2 | 2016 | 230 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1693 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 1476 | 0.150 |
Why?
|
| Age Factors | 2 | 2010 | 1198 | 0.140 |
Why?
|
| Life Change Events | 1 | 2016 | 41 | 0.140 |
Why?
|
| Prevalence | 2 | 2016 | 1025 | 0.140 |
Why?
|
| GABA Agonists | 1 | 2014 | 17 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2021 | 2604 | 0.120 |
Why?
|
| Alcohol Deterrents | 1 | 2013 | 9 | 0.120 |
Why?
|
| Risk-Taking | 1 | 2014 | 128 | 0.120 |
Why?
|
| Logistic Models | 1 | 2016 | 995 | 0.120 |
Why?
|
| Diltiazem | 1 | 2013 | 11 | 0.120 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 51 | 0.110 |
Why?
|
| Verapamil | 1 | 2013 | 23 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 96 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 77 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2014 | 135 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 72 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 426 | 0.110 |
Why?
|
| Recurrence | 1 | 2014 | 690 | 0.110 |
Why?
|
| Motivation | 1 | 2014 | 291 | 0.110 |
Why?
|
| Internet | 1 | 2014 | 275 | 0.100 |
Why?
|
| Electrocardiography | 1 | 2013 | 290 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1084 | 0.100 |
Why?
|
| Token Economy | 1 | 2010 | 33 | 0.100 |
Why?
|
| Affect | 1 | 2011 | 104 | 0.090 |
Why?
|
| Income | 1 | 2010 | 102 | 0.090 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 88 | 0.090 |
Why?
|
| Substance Abuse Detection | 1 | 2010 | 92 | 0.090 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 127 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 95 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 346 | 0.090 |
Why?
|
| Sleep | 1 | 2011 | 188 | 0.090 |
Why?
|
| Adolescent | 3 | 2016 | 6897 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2009 | 75 | 0.080 |
Why?
|
| Heart Rate | 1 | 2011 | 357 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2010 | 735 | 0.080 |
Why?
|
| Cognition | 1 | 2011 | 348 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2011 | 587 | 0.080 |
Why?
|
| Arkansas | 1 | 2014 | 2100 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 642 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 671 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2006 | 50 | 0.070 |
Why?
|
| Combat Disorders | 1 | 2006 | 42 | 0.070 |
Why?
|
| Child | 2 | 2016 | 7341 | 0.070 |
Why?
|
| Psychometrics | 1 | 2006 | 241 | 0.070 |
Why?
|
| Comorbidity | 1 | 2006 | 663 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2006 | 368 | 0.060 |
Why?
|
| Cocaine | 2 | 2017 | 184 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2023 | 120 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2013 | 89 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 17 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 309 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2021 | 118 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 596 | 0.050 |
Why?
|
| United States | 1 | 2010 | 5217 | 0.040 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 7 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1304 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2019 | 147 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1048 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 539 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2019 | 1361 | 0.030 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 2620 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 48 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 83 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 59 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 166 | 0.030 |
Why?
|
| Calcium Channels, L-Type | 1 | 2013 | 63 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 206 | 0.030 |
Why?
|
| Placebos | 1 | 2011 | 90 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 514 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 259 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 214 | 0.020 |
Why?
|
| Aged | 1 | 2014 | 10054 | 0.010 |
Why?
|